Paul Simon

Paul Simon

Auto-generated profile, based on publicly available information

Paul Simon

Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2003 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PSP Simon
P Simon
The first tissue engineered decellularized porcine heart valve, Synergraft (Cryolife Inc., USA) was introduced in Europe as an alternative to conventional biological valves. This is the first report of the rapid failure of these new grafts in a small series. In 2001, 2 model 500 and 2 model 700 Synergraft valves were implanted in four male children (age 2.5-11 years) in the right ventricular outflow tract as a root. Two patients had a Ross operation and two had a homograft replacement. The cryopreserved Synergraft valves appeared macroscopically unremarkable at implantation. Recovery from surgery was uneventful and good valve function was demonstrated postoperatively. Three children died, two suddenly with severely degenerated Synergraft valves 6 weeks and 1 year after implantation. The third child died on the 7th day due to Synergraft rupture. Subsequently the fourth graft was explanted prophylactically 2 days after implantation. Macroscopically all four grafts showed severe inflammation starting on the outside (day 2 explant) leading to structural failure (day 7 explant) and severe degeneration of the leaflets and wall (6 weeks and 1 year explant). Histology demonstrated severe foreign body type reaction dominated by neutrophil granulocytes and macrophages in the early explants and a lymphocytic reaction at 1 year. In addition significant calcific deposits were demonstrated at all stages. Surprisingly pre-implant samples of the Synergraft revealed incomplete decellularization and calcific deposits. No cell repopulation of the porcine matrix occurred. The xenogenic collagen matrix of the Synergraft valve elicits a strong inflammatory response in humans which is non-specific early on and is followed by a lymphocyte response. Structural failure or rapid degeneration of the graft occurred within 1 year. Calcific deposits before implantation and incomplete decellularization may indicate manufacturing problems. The porcine Synergraft treated heart valves should not be implanted at this stage and has been stopped.

1 February 2004 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
ERErwin Rieder
Erwin Rieder
MKMarie-Theres Kasimir
Marie-Theres Kasimir
GSGerd Silberhumer
Gerd Silberhumer
GSGernot Seebacher
Gernot Seebacher
EWErnst Wolner
Ernst Wolner
GWGuenter Weigel
Guenter Weigel

11 September 2007 in Circulation
Verified
Journal Article
Closed access
TWThomas Walther
Thomas Walther
PSPaul Simon
Paul Simon
TDTodd Dewey
Todd Dewey
GWGerhard Wimmer-Greinecker
Gerhard Wimmer-Greinecker
VFVolkmar Falk
Volkmar Falk
MMMichael Mack
Michael Mack
Background— To evaluate initial multicenter results with minimally invasive transapical aortic valve implantation (TAP-AVI) for high risk patients with aortic stenosis. Methods and Results— TAP-AVI was performed via a small anterolateral minithoracotomy with or without femoro-femoral extracorporeal circulation (ECC) on the beating heart. A pericardial xenograft fixed within a stainless steel, balloon expandable stent (Edwards SAPIEN THV, Edwards Lifesciences) was used. Fifty-nine consecutive patients (81±6 years, 44 female) were operated on from 02/06 until 10/06 at 4 centers using fluoroscopic and echocardiographic visualization. Average EuroSCORE predicted risk for mortality was 27±14%. TAP valve positioning was performed successfully in 53 patients, 4 required early conversion to sternotomy. Implantation (23-mm valves in 19 and 26-mm valves in 40 patients) was performed on the beating heart during brief periods of rapid ventricular pacing. Thirty-one patients were operated on without cardiopulmonary bypass. Neither coronary artery obstruction nor migration of the prosthesis was observed, and all valves had good hemodynamic function. Echocardiography revealed minor paravalvular leakage in 26 patients (trace in 11, mild in 12, and severe in 3). Eight patients died in-hospital (13.6%) without any valve dysfunction. Actuarial survival was 75.7±5.9% at a follow-up interval of 110±77 days (range 1 to 255 days). Conclusions— TAP-AVI can be performed safely with good early results in high risk patients. Long-term valve performance as well as broader based applications of this promising approach will need to be studied.

1 May 2003 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
PDF file
MKM.-T. Kasimir
M.-T. Kasimir
ERE. Rieder
E. Rieder
GSG. Seebacher
G. Seebacher
GSG. Silberhumer
G. Silberhumer
EWE. Wolner
E. Wolner
PSP. Simon
P. Simon
Background: Tissue engineering of heart valves should avoid the disadvantages of conventional prostheses. In this study we tested different decellularization procedures for their potential of cell removal and their ability to preserve the matrix. Methods: Specimens of porcine aortic and pulmonary roots were treated with either trypsin or sodium-dodecyl-sulfate (SDS) or Triton-X 100® and sodium-deoxycholate with a range of concentrations. Tissue samples were then processed for scanning electron microscopy and laser scanning microscopy. Results: Trypsin achieved only incomplete decellularization and caused severe structural alterations of the matrix. In contrast SDS removed cells completely but caused strong structural alterations. Treatment with Triton-X100® and sodium-deoxycholate achieved both complete decellularization and preservation of the matrix structure. Conclusion: Techniques of decellularization are highly variable in efficiency and matrix preservation and was best achieved in our study with Triton-X100® and sodium deoxycholate.

7 January 2002 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RMRodrig Marculescu
Rodrig Marculescu
TLTrang Le
Trang Le
PSPaul Simon
Paul Simon
UJUlrich Jaeger
Ulrich Jaeger
BNBertrand Nadel
Bertrand Nadel
Most lymphoid malignancies are initiated by specific chromosomal translocations between immunoglobulin (Ig)/T cell receptor (TCR) gene segments and cellular proto-oncogenes. In many cases, illegitimate V(D)J recombination has been proposed to be involved in the translocation process, but this has never been functionally established. Using extra-chromosomal recombination assays, we determined the ability of several proto-oncogenes to target V(D)J recombination, and assessed the impact of their recombinogenic potential on translocation rates in vivo. Our data support the involvement of 2 distinct mechanisms: translocations involving LMO2, TAL2, and TAL1 in T cell acute lymphoblastic leukemia (T-ALL), are compatible with illegitimate V(D)J recombination between a TCR locus and a proto-oncogene locus bearing a fortuitous but functional recombination site (type 1); in contrast, translocations involving BCL1 and BCL2 in B cell non-Hodgkin’s lymphomas (B-NHL), are compatible with a process in which only the IgH locus breaks are mediated by V(D)J recombination (type 2). Most importantly, we show that the t(11;14)(p13;q32) translocation involving LMO2 is present at strikingly high frequency in normal human thymus, and that the recombinogenic potential conferred by the LMO2 cryptic site is directly predictive of the in vivo level of translocation at that locus. These findings provide new insights into the regulation forces acting upon genomic instability in B and T cell tumorigenesis.

31 May 2005 in Circulation
Verified
Journal Article
Closed access
ERErwin Rieder
Erwin Rieder
GSGernot Seebacher
Gernot Seebacher
MKMarie-Theres Kasimir
Marie-Theres Kasimir
EEEva Eichmair
Eva Eichmair
BWBirgitta Winter
Birgitta Winter
GWGuenter Weigel
Guenter Weigel
Background— Tissue-engineered or decellularized heart valves have already been implanted in humans or are currently approaching the clinical setting. The aim of this study was to examine the migratory response of human monocytic cells toward decellularized porcine and human heart valves, a pivotal step in the early immunologic reaction. Methods and Results— Porcine and human pulmonary valve conduits were decellularized, and migration of U-937 monocytic cells toward extracted heart valve proteins was examined in a transmigration chamber in vitro. Homogenized tissue specimens were size fractionated by SDS-PAGE. The decellularization procedure effectively reduced the migration of human monocytes toward all heart valve tissue. However, only the antigen reduction of human pulmonary valves abolished the monocytic response (wall, 0.88±0.19% versus 30.20±3.93% migrated cells [mean±SEM]; cusps, 0.10±0.06% versus 10.24±1.83%) and was significantly lower ( P <0.05) than that of the decellularized porcine equivalent (wall, 5.03±0.14% versus 24.31±2.38%; cusps, 3.18±0.38% versus 10.24±1.83%). SDS-PAGE of the pulmonary heart valve tissue revealed that considerable amounts of proteins with different molecular weights that were not detected in the human equivalent remain in the decellularized porcine heart valve. Conclusions— We describe for the first time that the remaining potential of decellularized pulmonary heart valves to attract monocytic cells depends strongly on whether porcine or human scaffolds were used. These findings will have an important impact on further investigations in the field of heart valve tissue engineering.